Onward Medical N.V., a medical technology company, focuses on developing therapies for spinal cord injuries in the Netherlands and internationally. The company engages in developing ARCEX, an external non-invasive platform that consists of a wearable stimulator and wireless programmer, which restores or enhances physical movement of hand and arm function to people with spinal cord therapy; and ARCIM, an implantable platform, which consists of an implantable pulse generator and lead that is placed near the spinal cord that enables long-paralyzed people to stand and walk again with little or no assistance. It also engages in developing Up-LIFT Trial to evaluate the safety and effectiveness of ARCEX Therapy in restoring strength and function of upper extremities in people with spinal cord injury. Onward Medical N.V. was founded in 2014 and is headquartered in Eindhoven, Netherlands.

Onward Medical N.V.

ONWARD Medical is a medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injuries. ONWARD Medical’s work builds on more than a decade of basic science and preclinical research conducted at the world’s leading neuroscience laboratories. ARC Therapy, which can be delivered by implantable (ARC-IM) or external (ARC-EX) systems, is designed to deliver targeted, programmed spinal cord stimulation to restore movement and other functions in people with spinal cord injury, ultimately improving their quality of life. 

ONWARD Medical has received nine Breakthrough Device Designations from the U.S. FDA encompassing both ARC-IM and ARC-EX. ARC-EX is an external, non-invasive platform consisting of a wearable stimulator and wireless programmer. Positive top-line data were reported in September 2022 from the company’s first pivotal study, called Up-LIFT, evaluating the ability of transcutaneous ARC Therapy to improve upper extremity strength and function. The company is now preparing marketing approval submissions for the U.S. and Europe. ARC-IM consists of an implantable pulse generator and lead placed near the spinal cord. The Company completed its first-in-human use of the ARC-IM neurostimulator in May 2022. 

ONWARD Medical is headquartered in Eindhoven, the Netherlands. It maintains a Science and Engineering Center in Lausanne, Switzerland, and has a growing US presence in Boston, Massachusetts. The Company has an academic partnership with .NeuroRestore, a collaboration between the Swiss Federal Institute of Technology (EPFL) and Lausanne University Hospital (CHUV). 

ONWARD

🎉 Congratulations to our Vice President, Clinical, Regulatory, & Quality, Dr. Erika Ross Ellison, for her recent election as President of the Institute of Electrical and Electronics Engineers IEEE Engineering in Medicine and Biology Society (EMBS), the world’s largest international society of biomedical engineers. 
 
We proudly celebrate Erika’s historic achievement. Her election marks the first time in the 72-year history of IEEE EMBS that a leader from industry will serve in this volunteer position. Erika will be the 7th woman in the society’s history to lead the organization. 
 
IEEE EMBS is driven by a mission to create innovations in healthcare technology for the benefit of all humanity. The group’s 12,000 members span 97 countries and include #researchers, #educators, #engineers and #clinicans. Their areas of expertise run wide and deep, including medical technology, #bioinformatics, #biotechnology, #robots. Many are also focused on the translation of science to clinical practice.  
 
We also celebrate this moment as an opportunity to further collaborate across the intersection of health and technology. As a company dedicated to developing groundbreaking solutions to serve the spinal cord injury (SCI) Community, having visibility and access to the most cutting-edge resources and talent is a true honor.  
 
Way to go, Erika! 🎉 
 
*All ONWARD Medical devices and therapies, including but not limited to ARC-IM®, ARC-EX®, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use.

#EmpoweringMovement #SCI

Looking forward to participating in BioCapital Europe in Amsterdam TODAY! 

The event, one of Europe’s leading life sciences investor conferences, is organized by venture capital fund EQT Group, an investor in our company.

During the conference, CEO Dave Marver will present and participate in 1:1 and group meetings with investors to discuss the Company’s leadership in neuroscience, including the use of our investigational ONWARD ARC-IM® Therapy paired with brain-computer interface (BCI) technology.  
  
Tickets are sold out, but we encourage you to watch the livestream by clicking on the link below to learn more about the latest advances in #medtech, #therapeutics, and #neuroscience. Don’t miss our presentation at 11:20 am CET today. 
 
#EmpoweringMovement #SCI #Innovation #BioCapitalEurope
 
*All ONWARD Medical devices and therapies, including but not limited to ARC-IM®, ARC-EX®, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use.
 
https://lnkd.in/gJNc-2qG


“There is no protocol for this. You must figure it out every day...” 
 
Kevin Babington, a former Olympian and equestrian champion with an SCI, and his wife Dianna recently shared a glimpse into their daily lives with our ONWARD team. Kevin had just experienced a medical setback and the resulting emotions were clear in our candid conversation about the struggles for people living with spinal cord injury.
 
Dianna openly shared how their lives have changed since Kevin’s injury during the 2019 Hampton Classic Horse Show. “There is no more cuddling on the couch, no spontaneous trips…it is everyday grinding, even with all the support that we have found within our community.” Dianna’s testimony was gripping and demonstrated a deep vulnerability that both moved and motivated us. 
 
Despite their challenges, Kevin and Dianna are optimistic things will get better and said they are cheering for companies like ONWARD that are dedicated to making new solutions a reality. Read more about the Babington’s work to bring hope to other equestrians with SCI through the The Kevin Babington Foundation.
 
*All ONWARD devices and therapies, including but not limited to ARC-IM®, ARC-EX®, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use.
 
#EmpoweringMovement #SCI

✨ Thanks to De 7, the podcast from Belgian newspaper De Tijd, for its deep dive on brain-computer interface (BCI) technology. The episode, which was in Dutch, examined the buzz behind last week’s news about Neuralink’s first human implant, what it means, and the opportunities for investors. 
 
The show also laid out the events leading up to the news, and noted “this is not a first, the Dutch company ONWARD already implanted one [BCI] several years ago.” 

Education around new scientific breakthroughs is vital to continue progress and prevent misinformation. We appreciate journalists who help the public learn more about this groundbreaking investigational technology that has the potential to be used in combination with our investigational ARC Therapy™ to improve the lives of those with spinal cord injuries or other movement disorders. 

*All ONWARD devices and therapies, including but not limited to ARC-IM®, ARC-EX®, and ARC Therapy, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use. 

#EmpoweringMovement #BCI #SCI

It was a pleasure to participate in the Degroof Petercam Healthcare Conference this month, where our CEO Dave Marver updated attendees on our progress to launch ARC-EX® later this year. 
 
Thank you to all who joined us. You are critical for our mission to provide innovative solutions to restore movement, function, and independence after spinal cord injury (SCI).

*All ONWARD devices and therapies, including but not limited to ARC-IM®, ARC-EX, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use.
  
#EmpoweringMovement #SCI #Investors

	Mar '21	Jun '21	Sep '21	Dec '21	Mar '22	Jun '22	Sep '22	Dec '22	Mar '23	Jun '23	Sep '23	Dec '23	Mar '24	Jun '24
net income	-6.39M -	-6.39M 0%	-10.77M 68.69%	-10.77M 0%	-8.00M 25.75%	-15.99M 100%	-8.39M 47.56%	-16.78M 100%	-9.64M 42.53%	-19.28M 100%	-8.46M 56.13%	-16.90M 99.78%	-9.13M 46.00%	-9.13M 0%
depreciation and amortization	62K -	62K 0%	102.50K 65.32%	102.50K 0%	171.50K 67.32%	343K 100%	196K 42.86%	392K 100%	164.50K 58.04%	329K 100%		397K -	217K 45.34%	217K 0%
deferred income tax						872.50K -	-798.50K 191.52%	-235.00K 70.57%	-302.50K 28.72%	-2.52M 733.88%
stock based compensation	1.00M -	1.00M 0%	3.28M 226.71%	3.28M 0%	389.50K 88.12%	389.50K 0%	456K 17.07%	456K 0%	585.50K 28.40%	585.50K 0%			664.50K -	664.50K 0%
change in working capital	-56K -	-56K 0%	-1.12M 1,905.36%	-1.12M 0%	-272.50K 75.73%	1.95M 814.86%	342.50K 82.42%	1.00M 193.43%	-283K 128.16%	-1.28M 351.94%		116K -	-414K 456.90%	-414K 0%
accounts receivables	-56K -	-56K 0%	-1.12M 1,905.36%	-1.12M 0%	-272.50K 75.73%	-545K 100%	342.50K 162.84%	685K 100%	-283K 141.31%	-566K 100%		1.06M -	-414K 139.17%	-414K 0%
inventory
accounts payables						2.49M -		320K -		-713K -		-941K -		3.10M -
other working capital								-1 -
other non cash items	1.65M -	1.65M 0%	2.30M 39.33%	2.30M 0%	1.64M 28.92%	295K 81.96%	923.50K 213.05%	621K 32.76%	281K 54.75%	3.78M 1,244.48%	9.04M 139.40%	3.19M 64.79%	1.26M 60.57%	1.26M 0%
net cash provided by operating activities	-3.72M -	-3.72M 0%	-6.21M 66.80%	-6.21M 0%	-6.07M 2.24%	-12.15M 100%	-7.27M 40.16%	-14.54M 100%	-9.20M 36.75%	-18.39M 100%		-13.88M -	-7.40M 46.66%	-7.40M 0%
investments in property plant and equipment	-22.50K -	-22.50K 0%	-23K 2.22%	-23K 0%	-77K 234.78%	-166K 115.58%	-116K 30.12%	-251K 116.38%	-143.50K 42.83%	-303K 111.15%		-119K -	-12K 89.92%	-12K 0%
acquisitions net
purchases of investments
sales maturities of investments
other investing activites			-1.12M -	-1.12M 0%	-6K 99.46%		-10.01M -	-20M 99.81%	-2.51M 87.46%	-5M 99.36%		25M -	-3.75M 115.00%	-3.75M 0%
net cash used for investing activites	-22.50K -	-22.50K 0%	-1.14M 4,964.44%	-1.14M 0%	-83K 92.72%	-166K 100%	-10.13M 5,999.70%	-20.25M 100%	-2.65M 86.91%	-5.30M 100%		24.88M -	-3.76M 115.12%	-3.76M 0%
debt repayment										-1.04M -		-255K -
common stock issued														17.95M -
common stock repurchased
dividends paid
other financing activites	13.52M -	13.52M 0%	39.16M 189.68%	39.16M 0%	-157.50K 100.40%	-157.50K 0%	-121K 23.17%	-242K 100%	387.50K 260.12%	-263.00K 167.87%			8.82M -	8.82M 0%
net cash used provided by financing activities	13.52M -	13.52M 0%	39.16M 189.68%	39.16M 0%	-157.50K 100.40%	-315K 100%	-121K 61.59%	-242K 100%	387.50K 260.12%	774K 99.74%		39K -	8.82M 22,517.95%	8.82M 0%
effect of forex changes on cash	-16K -	-16K 0%	-34K 112.50%	-34K 0%	13K 138.24%	13K 0%	-25K 292.31%	-25K 0%	-26K 4%	-26K 0%			-263.50K -	-263.50K 0%
net change in cash	9.76M -	9.76M 0%	31.78M 225.70%	31.78M 0%	-6.30M 119.83%	-12.62M 100.21%	-17.54M 39.04%	-35.08M 100%	-11.49M 67.26%	-22.97M 100.01%		10.98M -	-2.61M 123.74%	-5.21M 100.04%
cash at beginning of period		16.14M -	25.89M 60.45%			89.46M -	76.84M 14.10%	76.84M 0%		41.76M -		18.79M -		29.77M -
cash at end of period	9.76M -	25.89M 165.42%	57.67M 122.71%	31.78M 44.90%	-6.30M 119.83%	76.84M 1,319.50%	59.30M 22.83%	41.76M 29.58%	-11.49M 127.50%	18.79M 263.58%		29.77M -	-2.61M 108.76%	24.55M 1,041.81%
operating cash flow	-3.72M -	-3.72M 0%	-6.21M 66.80%	-6.21M 0%	-6.07M 2.24%	-12.15M 100%	-7.27M 40.16%	-14.54M 100%	-9.20M 36.75%	-18.39M 100%		-13.88M -	-7.40M 46.66%	-7.40M 0%
capital expenditure	-22.50K -	-22.50K 0%	-23K 2.22%	-23K 0%	-77K 234.78%	-166K 115.58%	-116K 30.12%	-251K 116.38%	-143.50K 42.83%	-303K 111.15%		-119K -	-12K 89.92%	-12K 0%
free cash flow	-3.75M -	-3.75M 0%	-6.24M 66.41%	-6.24M 0%	-6.15M 1.36%	-12.31M 100.20%	-7.38M 40.02%	-14.79M 100.26%	-9.34M 36.85%	-18.69M 100.17%		-14.00M -	-7.41M 47.03%	-7.41M 0%

COM:ONWD

Wuhan Donglisheng M&E Technology Co., LTD

Last Close

4.66

22/11 16:35

Market Cap

179.38M

Beta: -

Volume Today

59.94K

Avg: -

Preview